Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pneumonia, Bacterial Clear all

Conditions: Pneumococcal Vaccines
Interventions: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 45
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more

Conditions: Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Interventions: ASN100, Placebo; Drug
Lead sponsor: Arsanis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 13 more

Conditions: COVID-19
Interventions: Previously admitted COVID-19 patients in intensive care units; Other
Lead sponsor: The University of Queensland; Other
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions: 2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap; Drug · Other
Lead sponsor: Cook County Health; Government
Eligibility: 16 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: V114, Prevnar 13™; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more

Conditions: Community Acquired Bacterial Pneumonia, Paraneumonic Effusion
Interventions: Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage; Procedure
Lead sponsor: Corewell Health West; Other
Eligibility: 0 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 13 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Houston, Texas

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Non-interventional; Other
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more

Conditions: Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions: Vabomere, Best Available Therapy; Drug
Lead sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.); Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 20
States / cities: Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Berkeley, California • Harbor City, California • Los Angeles, California + 12 more

Conditions: Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions: Colistimethate sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bronchiolitis, Viral, Pneumonia, Viral, Pneumonia, Bacterial
Interventions: Helmet CPAP; Device
Lead sponsor: Columbia University; Other
Eligibility: 1 Month to 5 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 21
States / cities: Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more

Conditions: Community Acquired Bacterial Pneumonia
Interventions: Efficacy of ceftaroline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Albany, New York

Conditions: Pneumococcal Vaccine
Interventions: MVX01, MVX01 Placebo; Biological
Lead sponsor: Matrivax Research and Development Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Savannah, Georgia • Knoxville, Tennessee

Conditions: Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: Lumbrokinase; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia, Pneumococcal
Interventions: V116, Pneumovax™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions: Urine sample collection; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more

Search by objective public record fields.

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Study of Fluid Collection of the Chest in Children With Pneumonia

A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole

Aerosolized and Intravenous Colistin in Healthy Adults

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Pediatric Helmet CPAP Pilot Study

An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia